Dec 2, 2025 7:30 AM Eastern Standard Time Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast Share Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth, Profitability and Shareholder Value PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc.(NYSE: ZTS), the world's leading animal health company, will host an Innovati ...

Core Viewpoint - Zoetis Inc. has received marketing authorization from the European Commission for Lenivia® (izenivetmab), a new antibody therapy aimed at reducing pain associated with osteoarthritis in dogs [1] Company Summary - Lenivia is designed to alleviate osteoarthritis pain in dogs for a duration of three months with a single injection [1] - The therapy utilizes novel binding properties to nerve growth factor (NGF), which is recognized as a significant mediator of pain and inflammation [1] - The development of Lenivia is based on over a decade of research [1]

Core Insights - Lenivia, a new antibody therapy, is set to reduce osteoarthritis (OA) pain in dogs for three months with a single injection if approved [1] Company Overview - The therapy targets osteoarthritis pain management in dogs, indicating a focus on animal health solutions [1] Industry Implications - The introduction of Lenivia could represent a significant advancement in veterinary medicine, particularly in pain management for pets [1]